U.S. Markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.1862%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.3841%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.1918%)
     
  • BTC-USD

    19,322.26
    -149.79 (-0.77%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Nutrien (NTR) Stock Moves -1.37%: What You Should Know

·3 min read

Nutrien (NTR) closed the most recent trading day at $88.68, moving -1.37% from the previous trading session. This change was narrower than the S&P 500's 1.71% loss on the day. Elsewhere, the Dow lost 1.7%, while the tech-heavy Nasdaq lost 0.18%.

Coming into today, shares of the producer of potash and other fertilizers had lost 6.67% in the past month. In that same time, the Basic Materials sector lost 5.04%, while the S&P 500 lost 8.68%.

Investors will be hoping for strength from Nutrien as it approaches its next earnings release. On that day, Nutrien is projected to report earnings of $4.20 per share, which would represent year-over-year growth of 204.35%. Our most recent consensus estimate is calling for quarterly revenue of $9.06 billion, up 50.35% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $16.55 per share and revenue of $39.61 billion. These totals would mark changes of +165.65% and +42.93%, respectively, from last year.

Any recent changes to analyst estimates for Nutrien should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Nutrien is currently a Zacks Rank #3 (Hold).

Valuation is also important, so investors should note that Nutrien has a Forward P/E ratio of 5.43 right now. This represents a no noticeable deviation compared to its industry's average Forward P/E of 5.43.

It is also worth noting that NTR currently has a PEG ratio of 0.68. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Fertilizers industry currently had an average PEG ratio of 0.63 as of yesterday's close.

The Fertilizers industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 160, putting it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Nutrien Ltd. (NTR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research